RecruitingDrug trialA Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid TumoursMulti-site, open-label, first-in-human study with 2 parts (dose escalation and dose expansion) in subjects with selected advanced solid tumours